Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $41.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its target price increased by Mizuho from $20.00 to $41.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other research analysts have also commented on the company. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $41.00 price objective (up from $37.00) on shares of Apellis Pharmaceuticals in a research report on Wednesday. Needham & Company LLC cut Apellis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 29th. Royal Bank Of Canada cut their target price on shares of Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 25th. Finally, Roth Mkm began coverage on shares of Apellis Pharmaceuticals in a research report on Friday, March 13th. They set a “buy” rating and a $31.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $34.11.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $40.41 on Thursday. Apellis Pharmaceuticals has a fifty-two week low of $16.10 and a fifty-two week high of $40.48. The business’s 50-day moving average is $22.24 and its 200-day moving average is $22.93. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 2.70. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of 310.87 and a beta of -0.19.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.86. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The company had revenue of $199.91 million during the quarter, compared to the consensus estimate of $199.28 million. During the same period in the previous year, the firm posted ($0.29) earnings per share. The company’s revenue was down 5.9% on a year-over-year basis. Equities research analysts expect that Apellis Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 5,928 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $129,052.56. Following the transaction, the insider owned 1,151,382 shares of the company’s stock, valued at $25,065,586.14. The trade was a 0.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Nur Nicholson sold 7,725 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $168,173.25. Following the completion of the sale, the insider directly owned 71,118 shares of the company’s stock, valued at approximately $1,548,238.86. The trade was a 9.80% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 115,537 shares of company stock worth $2,486,082. 6.50% of the stock is owned by company insiders.

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its holdings in shares of Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after purchasing an additional 1,373 shares during the period. Osaic Holdings Inc. raised its stake in Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after buying an additional 1,570 shares during the period. Allworth Financial LP boosted its stake in shares of Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after acquiring an additional 857 shares during the period. Quantbot Technologies LP acquired a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $64,000. Finally, EverSource Wealth Advisors LLC raised its stake in Apellis Pharmaceuticals by 338.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock valued at $94,000 after acquiring an additional 4,191 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Key Stories Impacting Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Mizuho raised its price target sharply from $20 to $41 (maintaining a neutral rating), implying modest upside from current levels and signaling greater confidence in valuation after the run-up. Mizuho raises PT
• Neutral Sentiment: Citigroup reaffirmed a neutral stance on Apellis (reporting coverage note). This keeps some institutional support for a non‑committal view despite other downgrades. Citigroup reaffirm
• Neutral Sentiment: JPMorgan is reporting a “neutral” rating in recent coverage notes — another signal that large banks are shifting to more cautious, hold/neutral stances instead of bullish calls. JPMorgan neutral
• Negative Sentiment: Multiple major sell‑side firms downgraded Apellis (many moving from strong‑buy/overweight to hold/neutral): Roth MKM, Cantor Fitzgerald, Jefferies, William Blair, Robert W. Baird, HC Wainwright, Raymond James, Needham and others. These coordinated rating cuts are the primary near‑term driver putting downward pressure on the stock as investors lock in gains after the rally. Representative coverage: Zacks analyst downgrades roundup Cantor Fitzgerald downgrade Raymond James lowered

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.